[Experimental and clinical studies of intravenous infusion of amikacin in acute respiratory tract infections].
Pharmacokinetic and clinical studies on amikacin (AMK) by intravenous drip (i.v.d.) infusion were performed, and the following results were obtained. 1. Serum concentrations of AMK were determined in 4 patients with normal renal function after 1 hour i.v.d. infusion of 200 mg of AMK. The mean peak serum concentration was 14.20 +/- 0.88 micrograms/ml at the termination of i.v.d. infusion and declined to 2.30 +/- 0.79 micrograms/ml at 4 hours later. The half-life was 1.55 +/- 0.28 hours. 2. Twenty-three patients with severe pulmonary infection received 1 hour i.v.d. infusion of 200 mg of AMK 2 to 3 times a day. Clinical response was good in 17 cases, fair in 4 and poor in 2. Thus, 73.9% of the patients responded to AMK. 3. No adverse effects were observed with the exception of tinnitus and hearing loss in 1 case. Therefore, it is thought that the i.v.d. infusion of AMK will be useful for treatment of severe infectious patients with bleeding tendency and emaciation.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006320:Hearing Tests; D006801:Humans; D007263:Infusions, Parenteral; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D007612:Kanamycin; D000583:Amikacin